Compare Crispr Therapeutics AG (CRSP) vs Super Group (SGHC) Limited Ordinary Shares (SGHC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Super Group (SGHC) Limited Ordinary Shares — how do they compare? Crispr Therapeutics AG trades at $53.39 (market cap $4.88B), while Super Group (SGHC) Limited Ordinary Shares trades at $11.29 (market cap $5.86B). The key difference: Super Group (SGHC) Limited Ordinary Shares is the larger of the two by market cap, and Super Group (SGHC) Limited Ordinary Shares pays a 1.73% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Super Group (SGHC) Limited Ordinary Shares for 1 Days on average.
| CRSP | SGHC | |
|---|---|---|
Market Cap | $4.88B | $5.86B |
Volume | 2,861,747 | 1,905,788 |
Sector | Health | Consumer Cyclical |
52-Week High | $73.97 | $15.59 |
52-Week Low | $44.34 | $8.52 |
Typical Hold Time | 77 Days | 1 Days |
Enterprise Value | $3.30B | $5.41B |
Dividend Yield | — | 1.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $50.44, down 3.65% amid bearish technical signals. The company shows negative profitability with -$581.60M net income and -4,101.26% net margin for 2025, though Q2 2026 EPS beat expectations. Positive analyst sentiment persists with 57.9% buy ratings and $67.83 consensus target. Recent clinical data presentations and CASGEVY commercial progress provide catalysts.
The stock faces fundamental challenges with persistent losses and negative cash flow from operations, but maintains Wall Street support for its gene-editing pipeline. Key risks include clinical trial outcomes and cash burn, while potential upside hinges on successful drug commercialization and upcoming data readouts through 2026.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Super Group (SGHC) Limited Ordinary Shares
Super Group (SGHC) Limited is a holding company for online sports betting and gaming businesses, operating the Betway sports betting brand and the Spin multi-brand online casino portfolio across markets in Europe, the Americas, and Africa.
Read more on SGHC →
